lead position
Sponsored content
Sponsored by
Maiwald
Features list
-
The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling
-
Dechert attorneys Christine C Levin and Irene Ayzenberg-Lyman provide an overview of the recent US Supreme Court decision, FTC v Actavis
-
Ylva Skoglösa and Camilla Lidén of Valea discuss the role and meaning of novelty in further medical use applications in Europe
-
Archana Shanker and Devinder Singh Rawat of Anand & Anand discuss the rise and regulation of biosimilar biologics in the Indian pharmaceutical market
-
The European Patent Convention is 40 years' old. To celebrate, Managing IP publishes a review of the EPC and its impact, alongside the regular regional articles of the Europe IP Focus
-
Marta Skrobot of Patpol explains how IP owners should choose between protection under industrial design or utility model law
Local Insights